Biotech firm Human Genome Sciences announced Thursday that it had rejected a takeover bid from pharmaceutical giant GlaxoSmithKline that valued it at just over 80% of its closing price Wednesday.
"Setting a HIRE standard...that's the Dunhill difference."
